Vijay Kumar, FDA's acting OTP director, says he's stepping down for reasons unrelated to agency turmoil, as the White House also weighs finalists for FDA commissioner.
June 30, 2026 10:47 AM EDT
Cell/Gene TxFDA+
FDA's acting director of cell and gene therapies to leave position
Zachary Brennan
Vijay Kumar is leaving his role as acting director of CBER’s Office of Therapeutic Products and will soon consider options both inside and outside the …
Following Vijay Kumar’s exit, acting CBER Director Karim Mikhail will also oversee a review office that has become a battleground…
The departure of Vijay Kumar follows a broader leadership shakeup at the FDA.
With the ink barely dry on outgoing commissioner Marty Makary’s resignation, another top regulator may be heading for the exit at…
Marty Makary's resignation leaves the agency with temporary directors in three top positions, and a number of newly instituted…
Vinay Prasad is leaving his post as director of the Center for Biologics Evaluation and Research.
Vinay Prasad, the controversial head of the FDA's vaccines and biologics division, will leave the agency, a government official…
